Drug Trial Radar · NCT07040787
Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Aug 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jul 8, 2025
Primary completion
Aug 17, 2025
Study completion Aug 17, 2025
Sponsor
- Lead sponsor
- Chengdu Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is being conducted to compare the drug-drug interaction of HRS-5965 with clopidogrel and clarithromycin in healthy subjects.
Conditions
- Complement Mediated Glomerular Diseases
- Hemolytic Anemia
Interventions
HRS-5965 CapsulesDrug
Oral HRS-5965 capsules.
ClopidogrelDrug
Oral clopidogrel.
ClarithromycinDrug
Oral clarithromycin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The maximum plasma concentration (Cmax)Time frame: Day 1 to day 12.
- Area under the concentration curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Day 1 to day 12.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.